Author:
Suzuki Kenta,Ogawa Daisuke,Kanda Takahiro,Fujimori Takeshi,Shibayama Yuki,Rahman Asadur,Ye Juanjuan,Ohsaki Hiroyuki,Akimitsu Kazuya,Izumori Ken,Tamiya Takashi,Nishiyama Akira,Miyake Keisuke
Abstract
AbstractRecent studies have shown that D-allose, a rare sugar, elicits antitumor effects on different types of solid cancers, such as hepatocellular carcinoma, non-small-cell lung cancer, and squamous cell carcinoma of the head and neck. In this study, we examined the effects of D-allose on the proliferation of human glioblastoma (GBM) cell lines (i.e., U251MG and U87MG) in vitro and in vivo and the underlying mechanisms. D-allose treatment inhibited the proliferation of U251MG and U87MG cells in a dose-dependent manner (3–50 mM). However, D-allose treatment did not affect cell cycles or apoptosis in these cells but significantly decreased the cell division frequency in both GBM cell lines. In a subcutaneous U87MG cell xenograft model, intraperitoneal injection of D-allose (100 mg/kg/day) significantly reduced the tumor volume in 28 days. These data indicate that D-allose-induced reduction in cell proliferation is associated with a subsequent decrease in the number of cell divisions, independent of cell-cycle arrest and apoptosis. Thus, D-allose could be an attractive additive to therapeutic strategies for GBM.
Funder
the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the united states in 2013–2017. Neuro Oncol. 22(12), 1iv1-iv96 (2020).
2. Stupp, R. et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA. 314(23), 2535–2543 (2015).
3. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
4. Stupp, R. et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25(3), iii93–iii101 (2014).
5. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370(8), 699–708 (2014).